Abstract
Cardiovascular disease (CVD) has become the leading cause of death for women. The incidence of CVD in women increases substantially with aging, probably because menopause diminishes the gender protection contributing to an adverse impact on cardiovascular risk variables. In this setting, the menopausal transition (MT) must be considered a critical period in women’s life because it leads to several adverse changes, especially with regard to lipid profile and modifies cardiovascular risk factors. Thus, it may be necessary to encourage lifestyle measures and therapeutic interventions such as hormone replacement therapy (HRT) throughout the MT to counteract or prevent these events. HRT for postmenopausal women has been available for more than 60 years. Ever since, HRT has been the subject of discussion and debate regarding its safety and efficacy; nowadays, it is well established that timing in the initiation as well as the type, dose and route of HRT are crucial for the success and benefit of HRT. Furthermore, a new study, published by the British Medical Journal, recently added interesting evidence to this debate, proving that menopausal hormone therapy saves lives and reduces disability.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW et al (2012) Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 97(4):1159–1168
Wang Q, Hassager C, Ravn P, Wang S, Christiansen C (1994) Total and regional body-composition changes in early postmenopausal women: age-related or menopause-related? Am J Clin Nutr 60(6):843–848
Sternfeld B, Dugan S (2011) Physical activity and health during the menopausal transition. Obstet Gynecol Clin North Am 38(3):537–566
Toth MJ, Tchernof A, Sites CK, Poehlman ET (2000) Menopause-related changes in body fat distribution. Ann N Y Acad Sci 904:502–506
Toth MJ, Tchernof A, Sites CK, Poehlman ET (2000) Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 24(2):226–231
Simkin-Silverman LR, Wing RR (2000) Weight gain during menopause. Is it inevitable or can it be prevented? Postgrad Med 108(3):47–50
Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340(23):1801–1811
Fu XD, Simoncini T (2007) Non-genomic sex steroid actions in the vascular system. Semin Reprod Med 25(3):178–186
Simoncini T, Genazzani AR (2003) Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148(3):281–292
Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Genazzani AR (2004) Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69(8–9):537–542
Simoncini T (2009) Mechanisms of action of estrogen receptors in vascular cells: relevance for menopause and aging. Climacteric 12(Suppl 1):6–11
Lerner DJ, Kannel WB (1986) Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111(2):383–390
Tracy RE (1966) Sex difference in coronary disease: two opposing views. J Chronic Dis 19(11):1245–1251
Tunstall-Pedoe H (1998) Myth and paradox of coronary risk and the menopause. Lancet 351(9113):1425–1427
Santoro N, Sutton-Tyrrell K (2011) The SWAN song: Study of Women’s Health Across the Nation’s recurring themes. Obstet Gynecol Clin North Am 38(3):417–423
Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B et al (2009) Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 54(25):2366–2373
Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B et al (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117(12):1016–1037
Henderson BE, Paganini-Hill A, Ross RK (1991) Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151(1):75–78
Guidelines for counseling postmenopausal women about preventive hormone therapy. American College of Physicians (1992). http://www.ncbi.nlm.nih.gov/pubmed/1443972. Ann Intern Med 117(12):1038–1041
Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ (1999) Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 130(7):545–553
Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270–282
Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL et al (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349(6):523–534
Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K (2004) Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140(3):184–188
Gass ML, Heights M, Manson JE, Cosman F, Hayes H, Grodstein F, et al (2012) North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. http://www.ncbi.nlm.nih.gov/pubmed/22367731. Menopause 19(3):257–271
Ghazal S, Pal L (2013) Perspective on hormone therapy 10 years after the WHI. Maturitas 76(3):208–212
Hodis HN, Mack WJ (2011) A “window of opportunity:” the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res 1379:244–252
Genazzani AR, Simoncini T (2007) Timing is everything. Gynecol Endocrinol 23(1):1–4
Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD et al (2010) Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95(7 Suppl 1):s1–s66
Smiley DA, Khalil RA (2009) Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem 16(15):1863–1887
Khalil RA (2013) Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol 86(12):1627–1642
Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L et al (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345:e6409
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333
Moyer VA (2013) Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive services task force recommendation statement. Ann Intern Med 158:47–54
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 International Society of Gynecological Endocrinology
About this chapter
Cite this chapter
Spina, S., Bernacchi, G., Cecchi, E., Genazzani, A.R., Simoncini, T. (2015). Cardiovascular Prevention at the Menopausal Transition: Role of Hormonal Therapies. In: Fauser, B.C.J.M., Genazzani, A.R. (eds) Frontiers in Gynecological Endocrinology. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-319-09662-9_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-09662-9_17
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09661-2
Online ISBN: 978-3-319-09662-9
eBook Packages: MedicineMedicine (R0)